Trial Profile
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Diagnostic use
- Acronyms ADRC proj 1; ADRCproj1
- 05 May 2023 Status changed from active, no longer recruiting to completed.
- 09 Jun 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.
- 09 Jun 2021 Planned primary completion date changed from 1 May 2021 to 1 May 2022.